Minnesota Headlines

Acute Ischemic Stroke (AIS) Market to Observe Stupendous Growth During the Forecast Period (2032) – Asserts DelveInsight | GNT Pharma (Nelonemdaz), Genentech, Supergene, Tasly, Angde, NuvOx, Healios

 Breaking News
  • No posts were found

Acute Ischemic Stroke (AIS) Market to Observe Stupendous Growth During the Forecast Period (2032) – Asserts DelveInsight | GNT Pharma (Nelonemdaz), Genentech, Supergene, Tasly, Angde, NuvOx, Healios

September 20
22:11 2022
Acute Ischemic Stroke (AIS) Market to Observe Stupendous Growth During the Forecast Period (2032) - Asserts DelveInsight | GNT Pharma (Nelonemdaz), Genentech, Supergene, Tasly, Angde, NuvOx, Healios
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 35+ key pharma and biotech companies are working in the Acute Ischemic Stroke therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The Acute Ischemic Stroke (AIS) market is anticipated to grow in the coming years owing to the launch of upcoming therapies and increased patient pool. Factors such as improving healthcare infrastructure in emerging economies, increased investment by pharmaceutical companies for research and development of improved drugs, and the rising number of pain management centers will also fuel the market in a positive direction.

DelveInsight’s “Acute Ischemic Stroke Market (AIS) Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Ischemic Stroke Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Acute Ischemic Stroke market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Ischemic Stroke Market

Acute Ischemic Stroke: An Overview

Acute Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- a mass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.

Treatment of acute ischemic stroke (AIS) consists of a multidisciplinary approach that, more than ever, requires the involvement of the critical care specialist. Antiplatelet therapy is an important cornerstone of treatment for preventing stroke and transient ischemic attacks (TIAs). Aspirin is the most commonly used agent since it is relatively safe, cheap, and widely available.

Acute Ischemic Stroke (AIS) Market Key Facts

  • As per the study conducted by Edward C Jauch et al. 2019, nearly 800,000 people suffer from strokes each year in the United States, and 82–92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability

  • According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke yearly. Of these, 5 million die, and another 5 million are left permanently disabled.

  • As per the Stroke Association of UK 2018, Up to 25% of childhood Ischemic strokes are linked to congenital heart disease.

Acute Ischemic Stroke (AIS) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Ischemic Stroke market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Acute Ischemic Stroke market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute Ischemic Stroke (AIS) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Acute Ischemic Stroke (AIS) Epidemiology Segmentation

  • Total Prevalent Cases of Acute Ischemic Stroke (AIS)

  • Diagnosed and Treatable Cases of Acute Ischemic Stroke (AIS)

  • Age-specific Prevalent Cases of Acute Ischemic Stroke (AIS) 

  • Gender-specific Prevalent Cases of Acute Ischemic Stroke (AIS)

Acute Ischemic Stroke (AIS) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ischemic Stroke market or expected to get launched during the study period. The analysis covers Acute Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Ischemic Stroke Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recent Developments in the Acute Ischemic Stroke (AIS) Therapeutics Market

Companies across the globe are working towards the development of new treatment therapies for Acute Ischemic Stroke. The dynamics of the Acute Ischemic Stroke market are anticipated to change in the coming years, owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

On Sept. 19, 2022, GNT Pharma provided an update on two phase III studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN). Nelonemdaz is a breakthrough multi-target neuroprotectant drug candidate, acting both as a moderately powerful NR2B subtype-selective NMDA receptor antagonist and a powerful antioxidant.

Learn How Acute Ischemic Stroke Market Will Evolve by 2032 @ 


Acute Ischemic Stroke (AIS) Therapeutics Analysis

There are approx. 35+ key companies which are developing therapies for Acute Ischemic Stroke. Currently, GNT Pharma has its Acute Ischemic Stroke drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Acute Ischemic Stroke (AIS) Therapeutic Market include:

Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO,  Angde Biotech Pharmaceutical, NuvOx Pharma, Healios, Acticor Biotech, Biogen,  ZZ Biotech, Revalesio Corporation, Shionogi & Co., Ltd.,  AbbVie, Pharming Group, Bristol-Myers Squibb, Roche, Clinuvel Pharmaceuticals, TrueBinding, Shin Poong Pharmaceutical,  Lumosa Therapeutics, NC Medical Research, JCR Pharmaceuticals, aptaTargets, PT. Prodia Stem Cell Indonesia and many others

Acute Ischemic Stroke (AIS) Emerging Drugs Covered in the report include:

• Nelonemdaz (GNT Pharma)

• Tenecteplase (Genentech)

• SP-8203 ( Shin Poong Pharmaceutical)

• NONO-SC (NoNO Inc.)

• MultiStem

• BMS-986177

• LT-3001

• Elezanumab

And Many more 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More – 


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Ischemic Stroke Competitive Intelligence Analysis

4. Acute Ischemic Stroke Market Overview at a Glance

5. Acute Ischemic Stroke Disease Background and Overview

6. Acute Ischemic Stroke Patient Journey

7. Acute Ischemic Stroke Epidemiology and Patient Population (In US, EU5, and Japan)

8. Acute Ischemic Stroke Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Ischemic Stroke Unmet Needs

10. Key Endpoints of Acute Ischemic Stroke Treatment

11. Acute Ischemic Stroke Marketed Products

12. Acute Ischemic Stroke Emerging Drugs and Latest Therapeutic Advances

13. Acute Ischemic Stroke Seven Major Market Analysis

14. Attribute Analysis

15. Acute Ischemic Stroke Market Outlook (In US, EU5, and Japan)

16. Acute Ischemic Stroke Access and Reimbursement Overview

17. KOL Views on the Acute Ischemic Stroke Market

18. Acute Ischemic Stroke Market Drivers

19. Acute Ischemic Stroke Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report: 



About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Leukocyte Adhesion Deficiency Market

“Leukocyte Adhesion Deficiency Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Leukocyte Adhesion Deficiency Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/